title: Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.
abstract: OBJECTIVE
  The aim of this Phase II study was to assess the efficacy and safety of vandetanib in combination with docetaxel in patients with pretreated advanced breast cancer.
  
  
  METHODS
  The primary study objective was to compare the number of progression events in patients receiving once-daily oral vandetanib (100 mg) in combination with docetaxel (100 mg/m(2) iv every 21 days) versus placebo plus docetaxel. Sixty-four patients were randomized to receive study treatment (n = 35, vandetanib; n = 29, placebo).
  
  
  RESULTS
  A slightly greater number of patients had experienced a progression event by the data cut-off in the vandetanib group (24 [69%]) compared with the placebo group (18 [62%]); HR = 1.19, two-sided 80% CI: 0.79-1.81; two-sided P = 0.59), suggesting that the addition of vandetanib to docetaxel did not affect the risk of disease progression compared with placebo plus docetaxel. The safety and tolerability profile of the combination therapy reflected those of both drugs as monotherapy agents.
  
  
  CONCLUSIONS
  In patients with advanced breast cancer, vandetanib plus docetaxel was generally well tolerated. Clinical benefit was not different to that observed with placebo plus docetaxel. However, due to the small patient number it was not possible to yield robust results, further research is required to identify predictive factors for patient selection.
authors.affiliation: Medical Oncology Department, St John Hospital, Bécsi út 132, 1032 Budapest, Hungary. katalin.boer@t-online.hu
authors.forename: Katalin
authors.initials: K
authors.lastname: Boér
authors.forename: István
authors.initials: I
authors.lastname: Láng
authors.forename: Antonio
authors.initials: A
authors.lastname: Llombart-Cussac
authors.forename: Inger
authors.initials: I
authors.lastname: Andreasson
authors.forename: Guillermo L
authors.initials: GL
authors.lastname: Vivanco
authors.forename: Nick
authors.initials: N
authors.lastname: Sanders
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Pover
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Murray
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D018450:Disease Progression; D000077143:Docetaxel; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D005060:Europe; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D016015:Logistic Models; D008875:Middle Aged; D018579:Patient Selection; D010880:Piperidines / Q000008:administration & dosage; D010919:Placebos; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000378:metabolism; D018570:Risk Assessment; D012307:Risk Factors; D013019:South Africa; D013624:Taiwan; D043823:Taxoids / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010880:Piperidines; D010919:Placebos; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; C512478:EGFR protein, human; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor; C452423:vandetanib